5NR Intrinsic Valuation and Fundamental Analysis - Nanobiotix SA

Watchlist Manager

Watchlist

Price: 26.5 EUR -5.42% Market Closed

Market Cap: €1.3B

	Nanobiotix SA F:5NR	FR
	NatWest Group PLC F:RYS	UK
R	Roper Technologies Inc F:ROP	US

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value for Nanobiotix SA.

Do our valuations actually work? See backtest results .

Fundamental Analysis

What Nanobiotix Does

Biotechnology Health Care

Nanobiotix is a French biotechnology company focused on cancer treatment. Its main product is a nanoparticle-based therapy that is designed to be injected into a tumor and activated by radiotherapy, with the goal of making radiation kill more cancer cells while limiting damage to healthy tissue. The company is still building this into an approved medical business rather than selling a broad range of medicines.

Headquarters: France FR
Employees: 100
IPO date: Oct 29, 2012

Read the full company overview

How Nanobiotix makes money

Cancer drug development

Nanobiotix develops cancer treatments based on its nanoparticle platform, including products designed to make tumors more responsive to radiation therapy and other treatments. The company focuses on advancing these medicines through testing, regulatory work, and partnerships with larger drug companies.

Customers: Hospitals, cancer doctors, and pharmaceutical partners involved in oncology treatment and drug development.
Revenue Model: It earns money through collaboration and licensing agreements, research funding from partners, and potential future sales or royalties from approved cancer therapies.

View Company Overview